GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acticor Biotech SA (STU:7V7) » Definitions » EV-to-EBIT

Acticor Biotech (STU:7V7) EV-to-EBIT : -0.69 (As of Jun. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Acticor Biotech EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Acticor Biotech's Enterprise Value is €11.19 Mil. Acticor Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-16.19 Mil. Therefore, Acticor Biotech's EV-to-EBIT for today is -0.69.

The historical rank and industry rank for Acticor Biotech's EV-to-EBIT or its related term are showing as below:

STU:7V7' s EV-to-EBIT Range Over the Past 10 Years
Min: -9.08   Med: 0   Max: 0
Current: -0.69

STU:7V7's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.71 vs STU:7V7: -0.69

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Acticor Biotech's Enterprise Value for the quarter that ended in Jun. 2023 was €62.78 Mil. Acticor Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-16.19 Mil. Acticor Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -25.79%.


Acticor Biotech EV-to-EBIT Historical Data

The historical data trend for Acticor Biotech's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acticor Biotech EV-to-EBIT Chart

Acticor Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial - - - -3.31 -4.99

Acticor Biotech Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only - -3.31 - -4.99 -

Competitive Comparison of Acticor Biotech's EV-to-EBIT

For the Biotechnology subindustry, Acticor Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acticor Biotech's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acticor Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Acticor Biotech's EV-to-EBIT falls into.



Acticor Biotech EV-to-EBIT Calculation

Acticor Biotech's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=11.190/-16.189
=-0.69

Acticor Biotech's current Enterprise Value is €11.19 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Acticor Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-16.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acticor Biotech  (STU:7V7) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Acticor Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 ) =EBIT / Enterprise Value (Q: Jun. 2023 )
=-16.189/62.782172
=-25.79 %

Acticor Biotech's Enterprise Value for the quarter that ended in Jun. 2023 was €62.78 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Acticor Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-16.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acticor Biotech EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Acticor Biotech's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Acticor Biotech (STU:7V7) Business Description

Traded in Other Exchanges
Address
82 Avenue du Maine, Wojo Building, Paris, FRA, 75014
Acticor Biotech SA is a clinical stage biopharmaceutical company. It is developing a treatment for cardiovascular emergencies, with a primary focus on Acute Ischemic Stroke.

Acticor Biotech (STU:7V7) Headlines

No Headlines